Last reviewed · How we verify

Centre Oscar Lambret — Portfolio Competitive Intelligence Brief

Centre Oscar Lambret pipeline: 1 marketed, 0 filed, 1 Phase 3, 7 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 1 Phase 3 7 Phase 2 7 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Blood collection Blood collection marketed
TEGAFUR URACIL - FOLINIC ACID TEGAFUR URACIL - FOLINIC ACID phase 3 Antimetabolite Thymidylate synthase Oncology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. GERCOR - Multidisciplinary Oncology Cooperative Group · 2 shared drug classes
  2. Hoffmann-La Roche · 2 shared drug classes
  3. Asan Medical Center · 1 shared drug class
  4. AstraZeneca · 1 shared drug class
  5. Australasian Gastro-Intestinal Trials Group · 1 shared drug class
  6. Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh · 1 shared drug class
  7. Barts & The London NHS Trust · 1 shared drug class
  8. Associazione Volontari Pazienti Oncologici · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Centre Oscar Lambret:

Cite this brief

Drug Landscape (2026). Centre Oscar Lambret — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/centre-oscar-lambret. Accessed 2026-05-16.

Related